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Abstract:  CZ48,  chemically  camptothecin-20-O-propionate  hydrate,  is  currently  under 
clinical investigation. The kinetics of the metabolite camptothecin (CPT) formation and of 
CZ48  depletion  in  mouse  and  human  liver  microsomes  in  the  presence  or  absence  of 
NADPH was examined. The formation rate of camptothecin in human liver microsomes 
was significantly higher than that in mouse with mean Kms of 1.9 and 0.5 nM and Vmaxs of 
9.3  and  2.2  pmol/min/mg,  respectively.  However,  the  apparent  intrinsic  clearance 
(Vmax/Km)  ratios  for  camptothecin  in  human  and  mouse  liver  microsomes  were  not 
significantly  different  from  each  other  (4.9  versus  4.4)  in  the  presence  of  NADPH.  
The  depletion  of  CZ48  in  human  microsomes  was  four  times  faster  with  4.55%  of  
CZ48  remaining  intact  while  in  mouse  19.11%  of  the  drug  remained  unchanged  after  
60  min.  These  results  suggest  that  there  is  a  remarkable  species  difference  of  CZ48 
biotransformation between human and mouse. The depletion rate of CZ48 in human liver 
microsomes is considerably higher than that in the mouse. 
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1. Introduction 
Metabolism studies are essential in the drug discovery and development process and are important 
to safety studies for the clinical development of drug candidates. Much progress has been made in 
recent years in understanding mechanisms of toxicities caused by drug metabolites and determining the 
numerous  factors  influencing  individual  exposure  to  products  of  drug  biotransformation.  The 
cytochrome P450 (CYP) superfamily is a large group of enzymes. CYPs are found to be the major 
enzymes involved in drug metabolism and biotransformation, accounting for approximately 75% of the 
total  number  of  metabolic  transformations  [1].  Glucuronidation  is  increasingly  recognized  as  an 
important clearance pathway in addition to that of P450 enzymes. The total contribution of P450 and 
UDP-glucuronosyltransferases in drug metabolism is reported to be more than 80% [2,3]. Hydrated 
crystalline camptothecin-20-propionate, CZ48, is under investigation for the treatment of cancer and is 
currently in phase 1 human clinical trials. This agent has shown remarkable anticancer activity and a 
lack of toxicity in nude mice. Differing from other camptothecin derivatives, CZ48 is stable in both 
mouse and human plasmas and the majority of the molecule remains in the intact lactone form. CZ48 
has a huge favorable therapeutic index ranging from 2 to 40 when treating human tumors grown as 
xenografts in nude mice, while other camptothecin derivatives and conventional anticancer agents have 
only a very narrow therapeutic window of 1 to 1.2. We previously reported our results in Cancer 
Research in 2009 [4]. The phase 1 trial with this agent started in late 2008 and more than 30 patients 
have been treated since then and the trial continues. To date the MTD (Maximum Tolerated Dose) has 
not  yet  been  reached  and  clinical  trials  are  ongoing  with  cohorts  of  three.  We  have 
pharmacokinetically analyzed the blood samples of 27 patients and observed that the concentration of 
CZ48  is  10  or  more  times  lower  in  human  blood  than  in  the  mouse,  while  the  concentration  of 
camptothecin (CPT) is multiple folds higher in human blood than in the  mouse (our unpublished 
results). The cause for this is probably that CZ48 has been biotransformed differently in the human 
body compared to the mouse. CPT is found to be the only identified metabolite of CZ48. 
A number of papers in literature report that human liver microsomes catalyze the metabolisms of 
different  types  of  drugs.  Both  human  liver  slices  and  microsomes  can  be  used  to  study  drug 
metabolism. Human liver microsomes are proven to be several times faster than slices [5–7], and 
clearance predictions are closer to in vivo values than are predictions from slices [8]. In this study, we 
examined the kinetics of the formation of the metabolite CPT and of the depletion of CZ48 in mouse 
and human liver microsomes for assessing the effect of species on the biotransformation of CZ48. The 
information  gained  concerning  the  species  differences  from  this  study  will  be  greatly  helpful  for 
extrapolating results from animals to humans. 
2. Results and Discussion 
The  conversion  of  CZ48  to  CPT  within  2  h  in  human  versus  mouse  liver  microsomes  was 
investigated  by  incubating  the  agent  in  HLM  (human  liver  microsomes)  and  MLM  (mouse  liver 
microsomes), respectively, in the absence of NADPH. The results are shown in Figure 1. 
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Figure 1. (a) Camptothecin (CPT) formation rate in human and mouse liver microsomes; 
(b) Accumulated formation of CPT in human and mouse liver microsomes. 
   
(a)  (b) 
Figure 1a shows the formation rate of the metabolite CPT in HLM and MLM, respectively, during 
the  period  of  the  incubation.  Figure  1b  summarizes  the  accumulated  formation  of  CPT  in  these 
microsomes within 120 min. As shown in Figure 1b, the accumulative amounts of CPT formed in 
MLM and HLM were 6.11 ±  0.107 and 0.78 ±  0.13 pmol/L, respectively. 
The incubation of CZ48 in HLM and MLM in the presence of NADPH for 2 h was subsequently 
performed and the CPT formation rate results are shown in Figure 2a. The relationship between the 
metabolism rate and the concentrations of CZ48 in HLM within the range of 0.15 to 5 μM was studied 
and plotted as shown in Figure 2b with Km 5.24 ±  0.23 μM and Vmax 19.65 ±  0.026 nmol/min/mg for 
HLM and Km 0.46 ±  0.13 μM and Vmax 2.20 ±  0.06 nmol/min/mg for MLM. 
Figure 2. (a) CPT formation rate in human and mouse liver microsomes in the presence of 
NADPH; (b) The kinetics of the CPT formation in human and mouse liver microsomes. 
   
(a)  (b) 
The incubation of CZ48 in HLM and MLM in the presence of UDPGA was also performed to study 
the effect of UDP-glucuronosyltransferases (UGTs) on the metabolism of CZ48 in humans and the 
mouse. Figures 3a and b respectively recorded the depletion rate of CZ48 and the formation rate of 
CPT in HLM and MLM. As shown in Figure 3A, the depletion rate of CZ48 in MLM was faster than 
that in HLM in the presence of UDPGA with a total CZ48 recovery of 75.0% in MLM and 92.3% in 
HLM. The CPT formation rate in MLM was 2.2–3.3 fold higher than that in HLM (Figure 3b). Int. J. Mol. Sci. 2012, 13  5501 
 
 
Figure 3. (a) Depletion rate of crystalline camptothecin-20-propionate (CZ48) in human 
and mouse liver microsomes in the presence of UDPGA. (b) CPT formation rate in human 
and mouse liver microsomes in the presence of UDPGA. 
   
(a)  (b) 
Compared to Figure 1a, Figure 2a clearly shows that the formation rate of the metabolite CPT in 
HLM and MLM was respectively 58.36 and 4.3 fold higher in the presence of NADPH than in the 
absence  of  NADPH,  suggesting  that  CZ48  metabolism  may  be  proceeded  by  a  CYP  
enzyme(s)-mediated biotransformation pathway. It was also found that the formation rate of CPT in 
HLM was 5.21 times higher than that in MLM in the presence of NADPH, which was the opposite of 
what happened in the absence of NADPH. Interestingly, in HLM, an Eadie-Hofstee curve for CPT 
formation was obtained when the rate of metabolism was plotted versus the concentration of CZ48 in 
the range from 0.15 to 5 µ M as shown in Figure 2b, clearly indicating auto-activation kinetics with the 
calculated Km and Vmax values of 0.42 ±  0.16 µM and 2.2 ±  0.056 nmol/min/mg, respectively. The 
atypical  kinetic  profiles  displayed  herein  may  not  only  be  substrate-dependent  but  also  enzyme  
source-dependent. CPT formation exhibited biphasic kinetics, which was characterized by an initial 
Michaelis-Menten-like increase in velocity as the substrate concentration increased. This resulted in an 
inaccurate apparent Vmax but an apparent Km. On the other hand, 99% of CZ48 was depleted within 2 h 
from human microsomal incubation in the presence of NADPH with a degradation half-life of 19 min, 
which was estimated by one-phase exponential decay non-linear regression analysis of the degradation 
time course data. Apparently, several P450 isoforms may be involved in microsomal metabolism as 
indicated  by  the  observed  kinetic  behavior.  Thus,  there  is  clearly  a  species  difference  in  the 
metabolism of CZ48 in liver microsomes between mice and humans. 
In the presence of NADPH, the formation rate of the metabolite CPT in human liver microsomes 
was significantly higher (p < 0.05) than that in mouse liver microsomes with mean Kms of 1.9 and  
0.5 nM and Vmaxs of 9.3 and 2.2 pmol/min/mg, respectively. However, the apparent intrinsic clearance 
ratios (Vmax/Km) for CPT metabolism in human and mouse liver microsomes were not significantly 
different from each other (4.9 versus 4.4) (p > 0.05). The depletion of CZ48 in human microsomes was 
multiple  times  faster  with  4.55%  of  the  CZ48  remaining  intact  compared  to  the  mouse  in  which 
19.11% of the drug unchanged after 60 min. In the absence of NADPH, the depletion of CZ48 in 
mouse liver microsomes was faster than that in human liver microsomes. These results suggest that 
there is a remarkable species difference in CZ48 metabolism in liver microsomes between human and 
the mouse, and also that the greater depletion rate of CZ48 in human liver microsomes is probably due Int. J. Mol. Sci. 2012, 13  5502 
 
 
to the involvement of human cytochrome P450s (CYPs); that is, the CZ48 metabolism in the human 
liver is probably a CYP-mediated process. CZ48 is designed to protect the lactone moiety of the 
molecule  while  circulating  in  the  body.  When  entering  into  tumors,  the  drug  reacts  with  tissue 
esterase(s) to release the active CPT. CZ48 was previously proven to be stable in human plasma [9]. 
The unexpected low concentration of CZ48 and the high concentration of the metabolite CPT detected 
in the blood of patients relative to the mouse are because the majority of the CZ48 absorbed by humans 
is  biotransformed  into  CPT  in  their  liver  due  to  CYP-mediated  metabolism.  This  CYP-mediated 
reaction may be depicted in the following way (Figure 4): 
Figure 4. CYP-mediated metabolism of CZ48 to CPT. 
 
The  CYP-mediated  hydroxylation  occurs  at  the  α-position  of  the  side  chain  of  CZ48.  This  
α-hydroxylation leads to a less stable intermediate product (compared to the parental CZ48), which 
could be easily cleaved at the original ester bond (i.e., the bond between 20-O and the acyl group) to 
yield the metabolite CPT. Unlike CZ48, CPT is not stable in human blood mainly because of the 
affinity of the carboxylate form of CPT to human serum albumin (HSA) [10]. The lactone form of 
CPT  has  great  anticancer  activity.  When  the  lactone  of  the  CPT  molecule  opens  to  become  a 
carboxylate, the agent loses 90% of its anticancer activity [11]. Protecting the lactone moiety of the 
molecule is thus critical to the success of the treatment of cancers in humans. 
UGT  isoenzymes,  expressed  in  various  tissues  including  liver  and  intestine,  catalyze  phase  II 
metabolic biotransformation. It has been widely reported that UGT activity also demonstrates species 
differences  between  mice  and  humans  in  some  common  metabolic  sites  such  as  liver,  lung,  and 
especially  intestine.  Figures  3A  and  3B  clearly  show  a  metabolic  difference  in  liver  microsomes 
between mouse and man, but the difference was not as dramatic as the CYP case. The depletion of 
CZ48 in HLM was somewhat slower than in MLM, implying that some specific UGT isoforms in 
MLM may be responsible for catalyzing CZ48 biotransformation to CPT a bit faster. Overall, the UGT 
effect on the metabolism of CZ48 in HLM and MLM was minimal. 
3. Experimental Section 
3.1. Chemicals 
HPLC-grade acetic acid,  dimethyl sulfoxide (DMSO), acetonitrile, dichloromethane and diethyl 
ether were obtained from Sigma-Aldrich (St. Louis, MO, USA). Chromatographic-grade water was 
produced by a Millipore Milli-Q System (Billerica, MA, USA). CZ48 and CZ44 (internal standard for 
HPLC quantification) were synthesized in-house by using reported procedures [12]. Camptothecin 
(with a purity of 99%) was purchased from China and used without further purification. Int. J. Mol. Sci. 2012, 13  5503 
 
 
3.2. CYP Activity 
The  activity  of  CYP  enzymes  was  evaluated  by  a  method  reported  by  Fujino  and  his  
co-workers [13,14]. Briefly, CZ48 was incubated with pooled human liver microsomes purchased from 
Sigma for up to 2 h at 37 ° C at a concentration of 1 mg/ml microsomal protein. All incubations were 
finally  performed  in  a  1  mL  reaction  solution  containing  1.3  mM  NADPH,  3.3  mM  
glucose-6-phosphate,  0.4  U/mL  Glucose-6-phosphate  dehydrogenase,  and  3.3  mM  MgCl2.  The 
reaction started by adding the microsomal protein solution following 3 to 5 min of prewarming. The 
reaction stopped by adding acetonitrile at the designated time. The mixture was extracted and the 
combined extracts were analyzed by HPLC following a reported procedure [15]. 
3.3. UGT Activity 
The activity of UGT was evaluated in the following way: all incubated microsomes were treated 
with alamethicin (50 ng alamethicin/mg microsomal protein), 10 mM magnesium chloride, 25 mM 
saccharolactone and CZ48 in 50 mM KPI buffer (pH 7.4) for 3 min at 37 ° C. The reactions initiated by 
the addition of 25 mM UDPGA were allowed to proceed for 120 min at 37 °C  and were then stopped 
by the addition of 50 µ L 94% acetonitrile/6% glacial acetic acid containing 100 µ g/mL cortisone as an 
internal standard. The mixture was extracted and the combined extracts were then analyzed by HPLC 
following our established method [15]. 
3.4. Kinetic Data 
Kinetic  data  (Km  and  Vmax)  were  obtained  using  the  Michaelis-Menten  equation:  
V = Vmax ×  S/(Kmax + S), where V is reaction rate, S is substrate concentration, and Vmax represents the 
maximum  rate  achieved  by  the  system,  at  maximum  (saturating)  substrate  concentrations.  The 
Michaelis constant Km is the substrate concentration at which the reaction rate is half of Vmax. The 
Curve  was  drawn  fitting  with  simple  weighting,  and  the  least-squares  minimization  procedure 
(regression analysis) was operated using Excel Solver. 
4. Conclusion 
The new anticancer agent CZ48 metabolizes in human liver microsomes much faster than in mouse 
liver  microsomes  in  the  presence  of  NADPH  and  slower  in  the  absence  of  NADPH,  indicating 
different metabolic pathways in humans versus mice. In human liver, the CYP isoenzymes play a 
major  role  in  catalyzing  the  formation  of  CPT  from  CZ48.  In  order  to  maintain  an  effective 
concentration of CZ48 circulating in the human body, efforts are required for identifying the individual 
CYP isoenzymes responsible for the α-hydroxylation at the side chain of CZ48, and, subsequently, a 
corresponding method for inhibiting this CYP-mediated metabolic process is needed. The effects of 
UGT isoenzymes on the metabolism of CZ48 in human and mouse liver microsomes exist, but are not 
significant. These results are useful for further development of CZ48 for clinical use, especially in 
designing the CZ48 dosing strategies for current and future human clinical trials. The study of the 
biotransformation of CZ48 in other organs and the identification of specific CYP (s) responsible for 
the discussed liver microsomal metabolism are to be performed and will be reported subsequently. Int. J. Mol. Sci. 2012, 13  5504 
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